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See Focus, pages 1219–1220Background & Aims: In long-term responder patients, it is unclear (range 1–78). RT region analysis was performed in 38/63 break-
whether lamivudine (LAM) monotherapy should be continued or
switched to a high-genetic-barrier analogue. This study aims at
assessing LAM efﬁcacy over a 5-year period and the residual risk
of drug resistance. The rate of HBsAg clearance and LAM long-
term safety proﬁle were also evaluated.
Methods: One hundred and ninety-one patients with chronic
HBeAg-negative hepatitis B successfully treated with LAM mono-
therapy for at least 5 years were included. Biochemical and viro-
logical tests were assessed every 3 months in all patients and
HBsAg quantiﬁcation was performed in 45/191. Reverse-trans-
criptase (RT) region was directly sequenced in virological break-
through patients.
Results: One hundred and ninety-one patients (148 males, med-
ian age 53 years, 72 with compensated cirrhosis) responding to
60-month LAM monotherapy continued to receive LAM mono-
therapy beyond the initial 5 years and were followed for an addi-
tional 36-month median period (range 1–108). Virological
response was maintained in 128/191 patients (67%) and HBsAg
clearance was observed in 15/128 (11.7%) after a 32-month med-
ian period (range 1–65). The 63 remaining patients (33%) showed
virological breakthrough after a 15-month median treatmentJournal of Hepatology 20
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VB, virological breakthrough.through patients and LAM resistant mutations were found in
37/38. No signiﬁcant side effects were observed.
Conclusions: In long-term responder patients, continuation of
LAM monotherapy resulted in persistent viral suppression in
most cases with undetectable HBV DNA by real-time PCR; more-
over, 11.7% of these patients cleared HBsAg. Selection of LAM
resistance, however, can still occur even after successful long-
term therapy, thus emphasising the importance of a careful viro-
logical monitoring.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Lamivudine (2.3-dideoxy-3-thiacytidine) was the ﬁrst nucleoside
analogue approved for treatment of chronic hepatitis B [1,2].
Clinical trials have shown that administration of LAM resulted
in a decrease in both serum HBV DNA and alanine aminotransfer-
ase (ALT) levels and an improved liver necroinﬂammation and
ﬁbrosis, thus reducing disease progression and development of
hepatocellular carcinoma [3–5]. The absence of clinical side
effects also assured a good compliance. However, a high rate of
LAM resistance (LAM-R) was reported; LAM-R progressively
increased during treatment at rates of 14–32% annually, exceed-
ing 70% after 5 years [6–8]. LAM-R development is responsible for
the treatment failure and may confer crossresistance to all
L-nucleosides, and might determine a reduced efﬁcacy of other
nucleos(t)ide analogue (NA) groups, thus limiting successive
treatment options [9]. Therefore, LAM is not recommended by
current guidelines for ﬁrst-line monotherapy and has been
substituted by the most potent NAs (entecavir or tenofovir) with
a higher resistance barrier [10,11]. Nevertheless, a certain per-12 vol. 56 j 1254–1258
Study burden 
Median FU = 36 mo (range 1-108)
636 naive patients 
treated with LAM 
445 (70%) 
developed resistance
191 long-term responders 
included in the study
At year 5
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centage of patients (25–30%) continue to maintain viral suppres-
sion after 5 years of continuous LAM monotherapy and it has yet
to be established if, in these patients, LAM should be continued or
switched to a drug with a better resistance proﬁle.
In this study, we assessed the efﬁcacy of further extending the
administration of monotherapy in a cohort of chronic hepatitis B
patients successfully treated with LAM for more than 5 years,
including the rate of HBsAg clearance and the residual risk of drug
resistance. Moreover, the long-term safety proﬁle of LAM was
evaluated.63 (33%) 
developed LAM resistance
128 (67%) maintained the 
viral suppression
Fig. 1. Flow chart of the study.
Table 1. Demographic, clinical and virological features of 191 long-term
lamivudine responder patients.
Median age, yr (range) 53 (24-76)
Gender, male,n (%) 148 (77.5)
Median body mass index 25
HBeAg negative, n (%) 191 (100)
Cirrhosis, n (%) 72 (37.7)
HDV, HCV, HIV co-infections 0
HBV DNA undetectable, n (%)
<380 IU/mla 51 (26.7)
<40 IU/mlb 140 (73.3)
<12 IU/mlc (tested patients n = 180) 148 (82.2)
Median treatment-duration, mo (range) 36 (1-108)
n = number of patients; aVersant HBV DNA 3.0 assay; bRoche Amplicor assay;
cCOBAS AmpliPrep/COBAS TaqMan HBV test.
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) Patients and methods
Patients
FromMarch1997 to September 2005, 636NA-naïve consecutive patientswithHBeAg
negative chronic hepatitis Bwere treatedwith LAMmonotherapy (100 mg/dayorally)
in eight Italian centres (Bari, Foggia, Napoli, S. Giovanni Rotondo, Torino, Milano,
Palermo, Pisa). During the ﬁrst ﬁve years of treatment, 445/636 patients (70%) devel-
oped LAM-R, while 191 patients, who maintained a virological response for at least
5 years (long-term responders), continued to receive LAM monotherapy and were
included in this retrospective observational study (Fig. 1).
Serological examination
In the 191 long-term responders, serological markers for HBV (HBsAg, HBeAg, anti-
HBe), hepatitis C (anti-HCV), hepatitis D (anti-HDV), and HIV (anti-HIV) were
tested using commercially available immunoassay kits. All patients were moni-
tored every 3 months for liver function tests and HBV DNA levels. HBV viremia
was assessed at inclusion in the study (5 years) using a third generation branched
DNA (Versant HBV DNA 3.0 assay; Bayer Healthcare Tarrytown, NY, USA with a
sensitivity limit of 380 IU/ml) or Roche Amplicor assay (Roche Diagnostic Sys-
tems, Branchburg, NJ, USA, limit of detection approximately 40 IU/ml). A conver-
sion factor of 5.26 copies/IU was adopted for conversion of copies/ml to IU/ml.
More recently, a quantitative real-time PCR assay, the COBAS AmpliPrep/COBAS
TaqMan HBV test (Roche Molecular Systems, Inc. Branchburg, NJ, USA) with a
lower limit of detection of 12 IU/ml was utilised. After 5 years of LAM therapy,
a stored serum sample was available for 180/191 patients and in these patients
HBV DNA was re-assessed using a real time PCR assay (<12 IU/ml).
In patients who experienced a virological breakthrough (>1 log10 increase in
HBV DNA serum levels compared with on-treatment nadir, conﬁrmed in two con-
secutive samples), molecular analysis of the HBV reverse transcriptase region was
performed by direct sequencing (Trugene HBV, Siemens HealthCare Diagnostics
Inc. Tarrytown NY, USA) or the INNO-LiPA HBV DR v2 assay (Innogenetics, Gent,
Belgium) according to the manufacturer’s instructions. HBV genotypes were also
assessed by means of these methods.
In a subgroup of 45/191 patients, HBsAg serum levels were measured using a
commercial chemiluminescent immunoassay (Architect HBsAg quantitative,
Abbott Diagnostics, Wiesbaden Germany).
Statistical analysis
Data were expressed as median and range for discrete variables and as counts and
percentages for qualitative variables. The cumulative incidence of virological
breakthrough was assessed by the Kaplan–Meier method. All data were analysed
using the SPSS statistical software package (version 12; SPSS, Inc., Chicago, IL, USA).482784 0642 63211
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Fig. 2. Cumulative probability of virological breakthrough during extended
LAMmonotherapy over 5 years. Time 0 is the enrolment time point after 5 years
of viral suppression.Results
After 5 years of LAM monotherapy, 191 HBeAg-negative chronic
hepatitis B patients continued to have undetectable HBV DNA
(assay sensitivity limit was 380 IU/ml for 51 patients and 40 IU/
ml for 140 patients) and were included in the study. Median
age was 53 years (range 24–76), 148 were males, histological or
clinical diagnosis of cirrhosis was present in 72/191 patientsJournal of Hepatology 2012(37.7%) (all were Child A). All patients were negative for HDV,
HCV, HIV co-infections and continued to receive LAM mono-
therapy beyond the initial 5 years and were followed for an addi-
tional median period of 36 months (range 1–108) (Table 1).
During this period, 128/191 patients (67%) remained persis-
tently HBV DNA negative, while 63 experienced a virological
breakthrough (VB) (33%) after a median treatment of 15 months
(range 1–78 months) (Fig. 1). The cumulative probability of VBvol. 56 j 1254–1258 1255
Table 2. Resistance patterns of mutations in the reverse transcriptase region
in 37 out of 63 patients with virological breakthrough.
Mutation patterns No. of patients
rtL180M, rtM204I 5
rtL180M, rtM204V 11
rtL80I, rtM204I 2
rtM204I, rtA181T 1
rtL80V, rtM204I 1
rtL180M, rtA181V 2
rtV173L, rtM204V 1
rtM204I, rtV214A 2
rtL180M, rtM204V, rtQ215S 1
rtM204I 8
rtM204V 1
rtA181T 1
Wild-type 1
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Fig. 3. Cumulative probability of HBsAg clearance in 128 HBV DNA suppressed
patients during extended LAM monotherapy. Time 0 is the enrolment time
point after 5 years of viral suppression.
Table 4. Predictors of HBsAg loss.
Patients with 
HBsAg loss
n = 15
Patients without 
HBsAg loss
n = 118
p value
Age, yr, (median 
range)
53 (32-72) 52 (24-76) n.s.
Gender, male, n (%) 13 (86.6) 85 (75.2) n.s.
HBV DNA positive 
by real-time PCR
(LLD = 12 IU/ml), 
n (%)
3/15 (20) 14/118 (11.8) n.s.
Cirrhosis, n (%) 7 (46.6) 36 (30.5) n.s.
n.s., not signiﬁcant.
Research Articlestarting from month 60 of effective LAM therapy is shown in
Fig. 2. Analysis of HBV resistance-associated mutations was
performed in 37/63 VB patients and all but one showed LAM
resistance mutations (rtM204I, rtM204V, rtA181V, rtA181T)
(Table 2). Two different clusters of LAM mutations were found
in these patients: rtM204V + rtL180M and rtM204I alone or in
combination with rtL80I or rtL180M; all 37 tested patients were
infected by genotype D. Treatment was promptly modiﬁed after
VB and no LAM-resistant patient experienced elevation of ALT
levels (biochemical breakthrough). Baseline HBV DNA was
assayed using the most sensitive method (<12 IU/ml) to ascertain
whether a certain HBV DNA level was associated with the emer-
gence of LAM resistance during further treatment after the initial
5 years. A total of 32 samples were HBV DNA positive (HBV DNA
<100 IU/ml in 20 samples and <400 IU/ml in 12). A signiﬁcant
association was found between VB and HBV DNA detection using
the real-time PCR (Table 3), independent of HBV DNA cut-off lev-
els (e.g. 12–200 IU/ml, or >200 IU/ml), whereas patient character-
istics, such as age, gender, and cirrhosis did not differ between
the two groups. However, due to the low viremia, it was not pos-
sible to perform genotyping using commercial kits.
Treatment was well tolerated and no patient developed seri-
ous adverse events or required dose reduction.
Fifteen of the 128 patients (11.7%) with stable viral suppres-
sion cleared HBsAg after a median period of 32 months; in partic-
ular, ﬁve patients cleared HBsAg after 12 months, two after
24 months, two after 36 months, three after 48 months, two after
60 months, and one after 72 months (Fig. 3). No signiﬁcant asso-
ciation was found between HBsAg loss and patient characteris-
tics, such as age, gender, HBV DNA levels, and presence ofTable 3. Predictors of drug resistance development.
Patients w
n = 63
Age, yr, median (range) 52 (28-72
Gender, male, n (%) 51 (80.9)
HBV DNA positive by real-time PCR (LLD = 12 IU/ml), n (%) 15/57 (26
Cirrhosis, n (%) 27 (42.8)
⁄Fischer’s exact test (two tailed). n.s., not signiﬁcant.
1256 Journal of Hepatology 2012cirrhosis (Table 4). After anti-HBs seroconversion, 8/15 patients
discontinued LAM and no patient showed reactivation during a
median post-treatment follow-up of 22 months (range 2–72). In
45 additional long-term responders, serum HBsAg levels were
quantiﬁed in serum samples stored after 60 months of therapy
and were compared with those from the last available sample.
A decrease in HBsAg values was observed in 18 patients (40%);
in particular, HBsAg levels were <10 IU/ml in ﬁve and
10–100 IU/ml in six patients.Discussion
Data on prolonged LAMmonotherapy in HBeAg-negative patients
with chronic hepatitis B or cirrhosis are scarce and it has yet to beith LAM resistance Patients without LAM resistance
n = 128
p value
) 53 (24-76) n.s.
93 (72.6) n.s.
.3) 17/123 (13.8) 0.022*
45 (35.1) n.s.
vol. 56 j 1254–1258
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established if LAM should be continued or switched to a drug
with a higher genetic barrier in these patients.
To our knowledge, this is the ﬁrst study evaluating both the
efﬁcacy of continuing LAM monotherapy and the residual risk
of drug resistance in a large patients’ cohort with HBeAg-negative
chronic hepatitis B successfully treated with LAM for at least
5 years. Overall, our data demonstrate that in long-term responder
patients who continued treatment beyond a 5-year period, LAM
was effective. In fact, the majority of our patients (67%), followed
for an additional median period of 36 months (up to
108 months), maintained on-treatment a virological response,
with a lower risk of treatment failure compared to that observed
during the initial 5 years of treatment in the entire cohort. Never-
theless, this study demonstrates that persistent viral suppression
for more than 5 years does not guarantee the absence of LAM-R
development. In our cohort of long-term responder patients, one
third developed VB during further extended administration of
LAM monotherapy with a trend to plateau after the 48-month
level, although patients with such a long period of continuous
treatment were few.
The appearance of LAM resistant mutants was documented by
genotypic analysis in all but one tested patient, conﬁrming that
viral breakthrough was related to antiviral drug resistance. Fac-
tors associated with the late emergence of resistant mutants in
these long-term responders are poorly deﬁned. Naturally, a possi-
ble decline in adherence cannot be completely ruled out [12,13],
even if all patients assured their adherence to treatment during
quarterly visits. In a single Japanese study, 21/98 (21%) LAM
responder patients showed emergence of YMDD mutants follow-
ing the completion of the 5-year treatment period; univariate
analysis showed that only age (>50 years) inﬂuenced the emer-
gence of the YMDD mutants [14]. The major caveat of our study
was the different cut-off values for HBV DNA in the different
assays used by the eight centers. To partially overcome this limit,
all available serum samples at baseline were tested by real-time
PCR assay. As expected, the presence of low levels of residual
viremia at inclusion in the study was found to be associated with
a signiﬁcantly higher risk of LAM resistance development, there-
fore a switch to another NA should be considered in these cases.
The late risk of LAM-R development demonstrated by our
results even in patients who were HBV DNA negative by real-time
PCR at the inclusion in the study indicates that a careful virolog-
ical monitoring is required in order to immediately diagnose
treatment failure and adopt a timely rescue therapy. In fact, reg-
ular virological monitoring permitted us to modify therapy
before a biochemical breakthrough and disease progression, thus
suggesting that, in a compliant patient, LAM monotherapy can be
safely continued even in those with advanced liver disease, while
a switch to a third generation analogue should be considered in
patients with a poor compliance.
An interesting observation of our study is that clearance of
HBsAg can be achieved even in HBeAg-negative patients treated
with a ﬁrst generation nucleoside analogue therapy. HBsAg clear-
ance is considered the ideal end point of chronic hepatitis B ther-
apy, but it is rarely documented in NA-treated patients and
exceptionally in those who are HBeAg-negative. In accordance
with current guidelines [10], LAM was discontinued in 8/15
patients after HBsAg clearance and none experienced HBsAg
seroreversion during post-treatment follow-up. In addition, a
decrease in serum HBsAg levels was observed in 40% of the
patients who were HBsAg positive at the end of the study.Journal of Hepatology 2012Recently, several studies have demonstrated that on-treatment
HBsAg quantiﬁcation is a useful tool to predict the response to
Peg-IFN treatment, whereas its role during NA treatment has
been scarcely investigated [15–19]. Gramenzi et al. studied
HBsAg kinetics in the sera of 42 HBeAg-negative patients treated
with LAM monotherapy for a prolonged period and found that in
six on-treatment responders, lamivudine was associated with a
steady HBsAg decrease up to its disappearance in two cases
[20]. In our study, HBsAg kinetics during the ﬁrst 6 months of
therapy was not investigated, however, a decline of serum HBsAg
levels in patients maintaining virological response was noted,
which would appear to indicate that HBsAg measurement could
be a tool to identify patients likely to proﬁt from continuing ther-
apy, although no positive predictors of HBsAg clearance could be
identiﬁed.
A secondary aim of our study was to investigate the long-term
safety proﬁle of lamivudine. In a large cohort of patients with
HBeAg-positive compensated hepatitis B, Lok et al. demonstrated
that lamivudine treatment for up to 6 years had an excellent
safety proﬁle despite an increasing rate of drug resistant mutants
over time [6]. In agreement with these data, our study showed
that lamivudine is safe even in patients with a therapy prolonged
up to 14 years.
In conclusion, our results demonstrate that continuation of LAM
monotherapy in long-term responder patients results in persistent
viral suppression in most cases with undetectable HBV DNA by
real-time PCR; moreover, 11.7% of these patients cleared HBsAg.
However, selection of LAM resistancemight still occur, although less
frequently, evenafter aprolonged successful therapy, thus emphasis-
ing the importance of a careful virological monitoring.Conﬂict of interest
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